Guardant Health, Inc. is expected to announce its quarterly earnings on Wednesday, May 6th, with a consensus estimate of -0.47 EPS.
Guardant Health, Inc. experienced a price drop of $6.08 (-6.87%) in the current session, trading at $82.42. The trading volume is at $1 million, 52.71% higher than the average.
In the latest quarterly earnings reported on February 18th, Guardant Health, Inc. had a consensus estimate EPS of -0.42. The company reported a net income of -$128.49 million.
Guardant Health, Inc. shows a net change in cash of -$201.81 million, ending the period with $378.20 million in cash. Operating cash flow was -$14 million, and debt repayment stood at -$372.88 million.
The company reported a revenue of $281.27 million, with a gross profit of $181.77 million. Guardant Health, Inc. faced operating expenses of $302.58 million, resulting in a net income of -$128.49 million.
Key ratios indicate a net profit margin of -45.68%, return on equity at 129.39%, and a debt ratio of 83.55%.
Guardant Health, Inc. holds total assets of $2 billion, with $1.47 billion in current assets. Total liabilities amount to $2.11 billion, including long-term debt of $1.68 billion.
This comprehensive analysis provides insights into Guardant Health, Inc.'s financial performance and position in the market.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.